COPD

The results of a recent UK study reveal that psychological distress, whether considered low or moderate, can increase a patient’s risk for chronic obstructive pulmonary disease, arthritis, and cardiovascular disease.

A new device intended to treat breathing difficulty associated with severe emphysema has been approved by the FDA.

Even though patients with advanced chronic obstructive pulmonary disease (COPD) can suffer from the same distressing symptoms as those with end-stage cancer, they are less likely to receive palliative care than those with other terminal illnesses.

The study aimed to analyze whether age, gender, socioeconomic factors, comorbidity, and medication may affect the risk of lung cancer in patients with COPD.

In a recent study, researchers set out to identify the reasons why prescribers and pharmacists continue to prescribe NS β‐blockers despite the guidelines recommending against it.

Chronic obstructive pulmonary disease (COPD) patients may face various exacerbations that may affect their daily live with the disease through symptoms.

A new study has found that patients with chronic obstructive pulmonary disease (COPD) better manage proper inhaler use with 1 branded single-use device than others.

Deprivation in patients with chronic obstructive pulmonary disease (COPD) is associated with increased emergency healthcare use, healthcare costs, and mortality rates, according to research.

COPD prevalence is increasing more rapidly in women, particularly in younger women, and COPD-related hospitalizations and deaths in women also surpass men.

Boehringer Ingelheim partnered with HealthPrize to deliver a platform that uses gamification, patient education, and tracking mechanics to help patients adherence with inhaler adherence, in a recent pilot study.

The trial’s primary endpoint was a statistically significant reduction of exacerbations in patients with chronic obstructive pulmonary disease (COPD).

Chronic obstructive pulmonary disease is a broad term used to include chronic bronchitis, emphysema, or a combination of both.

A landmark trial comparing triple therapy fluticasone furoate/umeclidinium/vilaterol (FF/UMEC/VI [Trelegy Ellipta]) versus FF/VI (Relvar; Breo) or FF/UMEC (Anoro) found the former is markedly better in reducing annual rate of on-treatment of moderate/severe exacerbations in patients with chronic obstructive pulmonary disease (COPD).

A new study comparing triple therapy for chronic obstructive pulmonary disease (COPD) against dual therapy resulted in a lower rate of moderate or severe COPD exacerbations and a lower rate of hospitalizations.

Childhood factors predisposed children to lung function decline and chronic obstructive pulmonary disease (COPD) as adults, according to 2 recent studies.

Chronic obstructive pulmonary disease (COPD) is a progressive, but treatable, disease characterized by airflow limitation and inflammation.

N-Acetylcysteine has several clinical uses. These include detoxification in acetaminophen overdose and improving outcomes in COPD exacerbations.

Asthma and chronic obstructive pulmonary disorder are chronic health conditions that need to be properly diagnosed to be managed effectively.

An international team of respiratory disease specialists looked back at 2017 and assembled a review of the current approaches to asthma and chronic obstructive pulmonary disease.

A recent pilot looked into whether using a personal robot in a patients home could prevent readmission rates for those recently hospitalized with COPD.

The FDA approved this nebulized long-acting muscarinic antagonist in December 2017, and it is expected to be launched this spring.

Up to 80% of women experience gastro-esophageal reflux disease during pregnancy.

Tiotropiumis is an inhaled anticholinergic bronchodilator approved by the FDA for long-term use in patients with asthma and COPD.

Excess weight may exacerbate asthma symptoms without affecting the efficacy of inhaled corticosteroids.

Glycopyrrolate inhalation solution is the first nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease.

The FDA has approved glycopyrrolate (Lonhala Magnair, Sunovion) inhalation solution, also known as SUN-101/eFlow, the first nebulized long-acting muscarinic antagonist (LAMA) for the treatment of chronic obstructive pulmonary disease (COPD).

The medication is indicated for the long-term, once-daily maintenance treatment of patients with chronic obstructive pulmonary disease.

Trelegy Ellipta is a combination of an inhaled corticosteroid, a long-acting muscarinic antagonist, and a long-acting beta2-adrenergic agonist for chronic obstructive pulmonary disease.

Chronic obstructive pulmonary disease (COPD)—irreversible—requires long-term adherence to pharmacotherapies for best outcomes.

Does this represent an opportunity for pharmacists to use such devices to help monitor adherence in patients?